Prevalence and Correlates of Chemotherapy-Induced Cognitive Impairment in Cancer Patients at Mahavir Cancer Sansthan, Patna: A Cross-Sectional Study

Cancer-related cognitive impairment (CRCI) significantly impacts the quality of life of cancer survivors, yet awareness of its effects remains limited. This cross-sectional study at Mahavir Cancer Sansthan, Patna, assessed the proportion of cognitive impairment among 140 chemotherapy-treated cancer patients using the Montreal Cognitive Assessment (MoCA). Findings revealed that 78.5% (110 patients) exhibited cognitive deficits, particularly in attention and memory, while only 30 showed no impairment. The study highlights the high prevalence of CRCI, emphasizing the need for early detection and supportive care in oncology practice. Although no significant correlations were found between cognitive impairment and variables like age, gender, or cancer stage, the results align with existing evidence of chemotherapy-induced cognitive dysfunction. The study underscores the necessity for further research to identify predictors of CRCI and develop targeted interventions. Oncology nurses play a crucial role in educating patients and managing cognitive side effects, ensuring better survivorship care. This study serves as a foundational step in addressing CRCI in Bihar’s cancer population, advocating for integrated cognitive assessments in treatment protocols to improve patient outcomes..